InMode Ltd. (INMD)
Stock Price Chart
Key Info
| Market Cap | 1.39B |
| Revenue (ttm) | 158.22M |
| Net Income (ttm) | 50.25M |
| Shares Out | 35.61M |
| EPS (ttm) | 1.16 |
| PE Ratio | 33.56 |
| Forward PE | 18.80 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 27, 2020 |
| Last Price | $38.93 |
| Previous Close | $39.80 |
| Change ($) | -0.87 |
| Change (%) | -2.19% |
| Day's Open | 39.60 |
| Day's Range | 38.62 - 39.80 |
| Day's Volume | 516,167 |
| 52-Week Range | 13.14 - 58.76 |
More Stats
| Market Cap | 1.39B |
| Enterprise Value | n/a |
| Earnings Date (est) | Nov 12, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 35.61M |
| Float | 16.26M |
| EPS (basic) | n/a |
| EPS (diluted) | 1.16 |
| FCF / Share | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 2.98% |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.66M |
| Short Ratio | 2.38 |
| Short % of Float | 10.20% |
| Beta | n/a |
| PE Ratio | 33.56 |
| Forward PE | 18.80 |
| P/FCF Ratio | n/a |
| PS Ratio | 8.76 |
| PB Ratio | 6.81 |
| Revenue | 158.22M |
| Operating Income | n/a |
| Net Income | 50.25M |
| Free Cash Flow | n/a |
| Net Cash | n/a |
| Net Cash / Share | n/a |
| Gross Margin | 86.04% |
| Operating Margin | n/a |
| Profit Margin | n/a |
| FCF Margin | n/a |
| ROA | 17.64% |
| ROE | 36.00% |
| ROIC | n/a |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
No financial data available for this stock yet.
Company Profile
Company Details
| Full Name | InMode Ltd. |
| Country | Israel |
| Employees | 251 |
| CEO | Moshe Mizrahy |
Stock Information
| Ticker Symbol | INMD |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: INMD |
| IPO Date | August 8, 2019 |
Description
InMode designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, Australia, and India, as well as indirectly through distributors in 46 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.